A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies
Completed
Meda Pharmaceuticals
Phase 3
2008-03-01
The purpose of this study is to determine if two allergy medications (azelastine and
fluticasone) are more effective than placebo or either medication alone (azelastine or
fluticasone)
A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies
Completed
Meda Pharmaceuticals
Phase 3
2007-12-01
The purpose of this study is to determine if two allergy medications (azelastine and
fluticasone) are more effective than placebo or either medication alone (azelastine or
fluticasone)
A Study Evaluating the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies
Completed
Meda Pharmaceuticals
Phase 3
2008-08-01
The purpose of this study is to determine if two allergy medications (formulated azelastine
and fluticasone product) are more effective than placebo or either medication alone
(azelastine or fluticasone)
A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies
Completed
Meda Pharmaceuticals
Phase 3
2009-04-01
The purpose of this study is to determine if the combination of two allergy medications
(formulated azelastine/fluticasone product)is more effective than placebo or either component
medication alone (azelastine or fluticasone).
Single Dose Pharmacokinetics of Intranasal Azelastine Delivered by a Fixed Combination With Fluticasone in Comparison to Azelastine Nasal Sprays
Completed
ClinResearch, GmbH
Phase 1
2010-08-01
The primary objective is to assess the effect of fluticasone propionate (FLU) on the relative
bioavailability (AUC0-∞) of azelastine hydrochloride (AZE) when administered as fixed AZE-FLU
combination product (TEST) compared to a similar formulation without containing FLU (i.e. AZE
alone; REF).
The secondary objectives are to compare the relative bioavailability (AUC0-∞) of AZE when
administered either as fixed AZE-FLU combination product (TEST) or as marketed AZE product
Astelin® Nasal Spray (COMP); To compare the effects of FLU on other pharmacokinetic
parameters of AZE (AUC0-tlast, CL/f, Cmax, tmax, t½); To assess adverse events.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
